Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System.

Gauberti M, Fournier AP, Docagne F, Vivien D, Martinez de Lizarrondo S.

Theranostics. 2018 Feb 2;8(5):1195-1212. doi: 10.7150/thno.22662. eCollection 2018. Review.

2.

Reduced spinal cord parenchymal cerebrospinal fluid circulation in experimental autoimmune encephalomyelitis.

Fournier AP, Gauberti M, Quenault A, Vivien D, Macrez R, Docagne F.

J Cereb Blood Flow Metab. 2018 Jan 29:271678X18754732. doi: 10.1177/0271678X18754732. [Epub ahead of print]

PMID:
29376456
3.

ADAMTS-4 in oligodendrocytes contributes to myelination with an impact on motor function.

Pruvost M, Lépine M, Leonetti C, Etard O, Naveau M, Agin V, Docagne F, Maubert E, Ali C, Emery E, Vivien D.

Glia. 2017 Dec;65(12):1961-1975. doi: 10.1002/glia.23207. Epub 2017 Aug 29.

PMID:
28850711
4.

Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin.

Fournier AP, Quenault A, Martinez de Lizarrondo S, Gauberti M, Defer G, Vivien D, Docagne F, Macrez R.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6116-6121. doi: 10.1073/pnas.1619424114. Epub 2017 May 22.

5.

Astrocytes regulate the balance between plasminogen activation and plasmin clearance via cell-surface actin.

Briens A, Bardou I, Lebas H, Miles LA, Parmer RJ, Vivien D, Docagne F.

Cell Discov. 2017 Feb 21;3:17001. doi: 10.1038/celldisc.2017.1. eCollection 2017.

6.

L. fermentum CECT 5716 prevents stress-induced intestinal barrier dysfunction in newborn rats.

Vanhaecke T, Aubert P, Grohard PA, Durand T, Hulin P, Paul-Gilloteaux P, Fournier A, Docagne F, Ligneul A, Fressange-Mazda C, Naveilhan P, Boudin H, Le Ruyet P, Neunlist M.

Neurogastroenterol Motil. 2017 Aug;29(8). doi: 10.1111/nmo.13069. Epub 2017 Mar 31.

PMID:
28370715
7.

Tissue-type plasminogen activator exerts EGF-like chemokinetic effects on oligodendrocytes in white matter (re)myelination.

Leonetti C, Macrez R, Pruvost M, Hommet Y, Bronsard J, Fournier A, Perrigault M, Machin I, Vivien D, Clemente D, De Castro F, Maubert E, Docagne F.

Mol Neurodegener. 2017 Feb 23;12(1):20. doi: 10.1186/s13024-017-0160-5.

8.

[Role of endothelial NMDA receptors in a mouse model of multiple sclerosis].

Macrez R, Vivien D, Docagne F.

Med Sci (Paris). 2016 Dec;32(12):1068-1071. doi: 10.1051/medsci/20163212008. Epub 2017 Jan 3. French. No abstract available.

9.

Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities.

Macrez R, Stys PK, Vivien D, Lipton SA, Docagne F.

Lancet Neurol. 2016 Sep;15(10):1089-102. doi: 10.1016/S1474-4422(16)30165-X. Epub 2016 Aug 8. Review.

PMID:
27571160
10.

Neuroendothelial NMDA receptors as therapeutic targets in experimental autoimmune encephalomyelitis.

Macrez R, Ortega MC, Bardou I, Mehra A, Fournier A, Van der Pol SM, Haelewyn B, Maubert E, Lesept F, Chevilley A, de Castro F, De Vries HE, Vivien D, Clemente D, Docagne F.

Brain. 2016 Sep;139(Pt 9):2406-19. doi: 10.1093/brain/aww172. Epub 2016 Jul 19.

PMID:
27435092
11.

The plasminogen activation system in neuroinflammation.

Mehra A, Ali C, Parcq J, Vivien D, Docagne F.

Biochim Biophys Acta. 2016 Mar;1862(3):395-402. doi: 10.1016/j.bbadis.2015.10.011. Epub 2015 Oct 19.

12.

Letter by Macrez et al. Regarding Article, "Preexisting Serum Autoantibodies Against the NMDAR Subunit NR1 Modulate Evolution of Lesion Size in Acute Ischemic Stroke".

Macrez R, Vivien D, Docagne F.

Stroke. 2015 Jul;46(7):e177. doi: 10.1161/STROKEAHA.115.009670. Epub 2015 May 28. No abstract available.

PMID:
26022638
13.

Normalization of Reverse Transcription Quantitative PCR Data During Ageing in Distinct Cerebral Structures.

Bruckert G, Vivien D, Docagne F, Roussel BD.

Mol Neurobiol. 2016 Apr;53(3):1540-1550. doi: 10.1007/s12035-015-9114-5. Epub 2015 Feb 7.

14.

Understanding the functions of endogenous and exogenous tissue-type plasminogen activator during stroke.

Docagne F, Parcq J, Lijnen R, Ali C, Vivien D.

Stroke. 2015 Jan;46(1):314-20. doi: 10.1161/STROKEAHA.114.006698. Epub 2014 Nov 13. Review. No abstract available.

PMID:
25395410
15.

Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system.

Hernangómez M, Carrillo-Salinas FJ, Mecha M, Correa F, Mestre L, Loría F, Feliú A, Docagne F, Guaza C.

Curr Pharm Des. 2014;20(29):4707-22. Review.

16.

Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier.

Krol S, Macrez R, Docagne F, Defer G, Laurent S, Rahman M, Hajipour MJ, Kehoe PG, Mahmoudi M.

Chem Rev. 2013 Mar 13;113(3):1877-903. doi: 10.1021/cr200472g. Epub 2012 Nov 19. Review. No abstract available.

PMID:
23157552
17.

Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders.

Montagne A, Gauberti M, Macrez R, Jullienne A, Briens A, Raynaud JS, Louin G, Buisson A, Haelewyn B, Docagne F, Defer G, Vivien D, Maubert E.

Neuroimage. 2012 Nov 1;63(2):760-70. doi: 10.1016/j.neuroimage.2012.07.018. Epub 2012 Jul 17.

PMID:
22813950
18.

CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation.

Hernangómez M, Mestre L, Correa FG, Loría F, Mecha M, Iñigo PM, Docagne F, Williams RO, Borrell J, Guaza C.

Glia. 2012 Sep;60(9):1437-50. doi: 10.1002/glia.22366. Epub 2012 May 31.

PMID:
22653796
19.

Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals.

Cassé F, Bardou I, Danglot L, Briens A, Montagne A, Parcq J, Alahari A, Galli T, Vivien D, Docagne F.

J Neurosci. 2012 Apr 11;32(15):5186-99. doi: 10.1523/JNEUROSCI.5296-11.2012.

20.

tPA in the injured central nervous system: different scenarios starring the same actor?

Lemarchant S, Docagne F, Emery E, Vivien D, Ali C, Rubio M.

Neuropharmacology. 2012 Feb;62(2):749-56. doi: 10.1016/j.neuropharm.2011.10.020. Epub 2011 Nov 7. Review.

PMID:
22079561
21.

Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults.

Rubio M, Villain H, Docagne F, Roussel BD, Ramos JA, Vivien D, Fernandez-Ruiz J, Ali C.

PLoS One. 2011;6(8):e23690. doi: 10.1371/journal.pone.0023690. Epub 2011 Aug 19.

22.

Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors.

Mestre L, Iñigo PM, Mecha M, Correa FG, Hernangómez-Herrero M, Loría F, Docagne F, Borrell J, Guaza C.

J Neuroinflammation. 2011 Aug 18;8:102. doi: 10.1186/1742-2094-8-102.

23.

Tissue plasminogen activator prevents white matter damage following stroke.

Correa F, Gauberti M, Parcq J, Macrez R, Hommet Y, Obiang P, Hernangómez M, Montagne A, Liot G, Guaza C, Maubert E, Ali C, Vivien D, Docagne F.

J Exp Med. 2011 Jun 6;208(6):1229-42. doi: 10.1084/jem.20101880. Epub 2011 May 16.

24.

The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells.

Correa F, Hernangómez-Herrero M, Mestre L, Loría F, Docagne F, Guaza C.

Brain Behav Immun. 2011 May;25(4):736-49. doi: 10.1016/j.bbi.2011.01.020. Epub 2011 Feb 16.

PMID:
21310228
25.

An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis.

Loría F, Petrosino S, Hernangómez M, Mestre L, Spagnolo A, Correa F, Di Marzo V, Docagne F, Guaza C.

Neurobiol Dis. 2010 Jan;37(1):166-76. doi: 10.1016/j.nbd.2009.09.020. Epub 2009 Oct 6.

PMID:
19815071
26.

The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis.

Correa FG, Mestre L, Docagne F, Borrell J, Guaza C.

Vitam Horm. 2009;81:207-30. doi: 10.1016/S0083-6729(09)81009-1. Review.

PMID:
19647114
27.

Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB.

Correa F, Hernangómez M, Mestre L, Loría F, Spagnolo A, Docagne F, Di Marzo V, Guaza C.

Glia. 2010 Jan 15;58(2):135-47. doi: 10.1002/glia.20907.

PMID:
19565660
28.

Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.

Cunningham O, Campion S, Perry VH, Murray C, Sidenius N, Docagne F, Cunningham C.

Glia. 2009 Dec;57(16):1802-14. doi: 10.1002/glia.20892.

29.

A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules.

Mestre L, Docagne F, Correa F, Loría F, Hernangómez M, Borrell J, Guaza C.

Mol Cell Neurosci. 2009 Feb;40(2):258-66. doi: 10.1016/j.mcn.2008.10.015. Epub 2008 Nov 19.

PMID:
19059482
30.

The endocannabinoid system is modulated in response to spinal cord injury in rats.

Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, Docagne F, Hagen C, Bisogno T, Watanabe M, Guaza C, Di Marzo V, Molina-Holgado E.

Neurobiol Dis. 2009 Jan;33(1):57-71. doi: 10.1016/j.nbd.2008.09.015. Epub 2008 Sep 30.

PMID:
18930143
31.

A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells.

Correa F, Docagne F, Mestre L, Clemente D, Hernangómez M, Loría F, Guaza C.

Biochem Pharmacol. 2009 Jan 1;77(1):86-100. doi: 10.1016/j.bcp.2008.09.014. Epub 2008 Sep 20.

PMID:
18848818
32.

Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.

Loría F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangómez M, Guaza C, Di Marzo V, Docagne F.

Eur J Neurosci. 2008 Aug;28(4):633-41. doi: 10.1111/j.1460-9568.2008.06377.x. Epub 2008 Jul 24.

PMID:
18657182
33.

HtrA1-dependent proteolysis of TGF-beta controls both neuronal maturation and developmental survival.

Launay S, Maubert E, Lebeurrier N, Tennstaedt A, Campioni M, Docagne F, Gabriel C, Dauphinot L, Potier MC, Ehrmann M, Baldi A, Vivien D.

Cell Death Differ. 2008 Sep;15(9):1408-16. doi: 10.1038/cdd.2008.82. Epub 2008 Jun 13.

34.

Therapeutic potential of CB2 targeting in multiple sclerosis.

Docagne F, Mestre L, Loría F, Hernangómez M, Correa F, Guaza C.

Expert Opin Ther Targets. 2008 Feb;12(2):185-95. doi: 10.1517/14728222.12.2.185 . Review.

PMID:
18208367
35.

Cannabinoid system and neuroinflammation: implications for multiple sclerosis.

Correa F, Docagne F, Mestre L, Loría F, Hernangómez M, Borrell J, Guaza C.

Neuroimmunomodulation. 2007;14(3-4):182-7. Epub 2007 Dec 5. Review.

PMID:
18073512
36.
37.

Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis.

Benito C, Romero JP, Tolón RM, Clemente D, Docagne F, Hillard CJ, Guaza C, Romero J.

J Neurosci. 2007 Feb 28;27(9):2396-402.

38.

Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.

Docagne F, Muñetón V, Clemente D, Ali C, Loría F, Correa F, Hernangómez M, Mestre L, Vivien D, Guaza C.

Mol Cell Neurosci. 2007 Apr;34(4):551-61. Epub 2007 Jan 16.

PMID:
17229577
39.

[Cannabinoid system and neuroinflammation:therapeutic perspectives in multiple sclerosis].

Mestre L, Correa F, Docagne F, Clemente D, Ortega-Gutiérrez S, Arévalo-Martín A, Molina-Holgado E, Borrell J, Guaza C.

Rev Neurol. 2006 Nov 1-15;43(9):541-8. Review. Spanish.

40.

The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection.

Mestre L, Correa F, Docagne F, Clemente D, Guaza C.

Biochem Pharmacol. 2006 Sep 28;72(7):869-80. Epub 2006 Aug 17.

PMID:
16914119
41.

TGFbeta1 regulates the inflammatory response during chronic neurodegeneration.

Boche D, Cunningham C, Docagne F, Scott H, Perry VH.

Neurobiol Dis. 2006 Jun;22(3):638-50. Epub 2006 Feb 28.

PMID:
16510291
42.

The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation.

Correa F, Mestre L, Molina-Holgado E, Arévalo-Martín A, Docagne F, Romero E, Molina-Holgado F, Borrell J, Guaza C.

Mini Rev Med Chem. 2005 Jul;5(7):671-5. Review.

PMID:
16026313
44.

Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation.

Docagne F, Campbell SJ, Bristow AF, Poole S, Vigues S, Guaza C, Perry VH, Anthony DC.

Eur J Neurosci. 2005 Mar;21(5):1205-14.

PMID:
15813930
45.

Sp1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription.

Docagne F, Gabriel C, Lebeurrier N, Lesné S, Hommet Y, Plawinski L, Mackenzie ET, Vivien D.

Biochem J. 2004 Oct 15;383(Pt 2):393-9.

46.

Transforming growth factor-beta and ischemic brain injury.

Buisson A, Lesne S, Docagne F, Ali C, Nicole O, MacKenzie ET, Vivien D.

Cell Mol Neurobiol. 2003 Oct;23(4-5):539-50. Review.

PMID:
14514014
47.

[Does transforming growth factor-beta (TGF-beta) act as a neuroprotective agent in cerebral ischemia?].

Docagne F, Ali C, Lesne S, Nicole O, MacKenzie ET, Buisson A, Vivien D.

J Soc Biol. 2003;197(2):145-50. Review. French.

PMID:
12910629
48.

CINC-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury.

Campbell SJ, Hughes PM, Iredale JP, Wilcockson DC, Waters S, Docagne F, Perry VH, Anthony DC.

FASEB J. 2003 Jun;17(9):1168-70. Epub 2003 Apr 22.

PMID:
12709409
49.

Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice.

Lesné S, Docagne F, Gabriel C, Liot G, Lahiri DK, Buée L, Plawinski L, Delacourte A, MacKenzie ET, Buisson A, Vivien D.

J Biol Chem. 2003 May 16;278(20):18408-18. Epub 2003 Mar 7.

50.

Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta 1 against NMDA-induced necrosis.

Docagne F, Nicole O, Gabriel C, Fernández-Monreal M, Lesné S, Ali C, Plawinski L, Carmeliet P, MacKenzie ET, Buisson A, Vivien D.

Mol Cell Neurosci. 2002 Dec;21(4):634-44.

PMID:
12504596

Supplemental Content

Loading ...
Support Center